Advicenne
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or co… Read more
Advicenne - Asset Resilience Ratio
Advicenne (ALDVI) has an Asset Resilience Ratio of 7.65% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Advicenne's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Advicenne's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €515.00K | 7.65% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €515.00K | 7.65% |
Asset Resilience Insights
- Limited Liquidity: Advicenne maintains only 7.65% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Advicenne Industry Peers by Asset Resilience Ratio
Compare Advicenne's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Advicenne (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Advicenne.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 34.17% | €3.25 Million | €9.51 Million | -0.09pp |
| 2023-12-31 | 34.26% | €4.25 Million | €12.41 Million | -24.12pp |
| 2022-12-31 | 58.38% | €8.32 Million | €14.26 Million | -8.81pp |
| 2021-12-31 | 67.18% | €12.69 Million | €18.88 Million | -2.68pp |
| 2020-12-31 | 69.87% | €16.77 Million | €24.00 Million | -12.39pp |
| 2019-12-31 | 82.26% | €18.85 Million | €22.92 Million | +1.96pp |
| 2018-12-31 | 80.30% | €26.64 Million | €33.17 Million | -14.18pp |
| 2017-12-31 | 94.47% | €36.48 Million | €38.62 Million | +45.86pp |
| 2016-12-31 | 48.62% | €1.58 Million | €3.26 Million | -3.13pp |
| 2015-12-31 | 51.75% | €1.54 Million | €2.98 Million | +7.10pp |
| 2014-12-31 | 44.65% | €1.44 Million | €3.22 Million | -- |